Bemarituzumab Improves Gastric Cancer Survival Response Rates
In a study presented at ASCO GI, adding Five Prime’s experimental targeted drug to a modified FOLFOX chemotherapy regimen significantly improved survival... Read More
Single-cell analysis of metastatic gastric cancer finds diverse tumor cell populations associated with patient outcomes
MD Anderson researchers identified two subtypes of peritoneal carcinomatosis, a form of gastric cancer, and developed gene expression signatures that can be... Read More
Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis
A study found that “cytoreductive” surgery combined with intraperitoneal chemotherapy improved survival for some gastric cancer patients but that the strategy should... Read More
Immunotherapy May Work Better Against Stomach Cancer When Combined with Chemo, Given Earlier
Immunotherapy for stomach cancer may work better if the therapy is delivered earlier in the course of disease and in combination with... Read More
Foundation Funds Major Expansion of Gastric Cancer Registry
The Gastric Cancer Foundation has committed $257,856 to fund a transformative expansion of the Gastric Cancer Registry in 2021. The funding will... Read More
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer
The targeted drug Cyramza combined with chemotherapy produced a disease-control rate of 81% in a trial of previously treated gastric cancer patients.
Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma
Gastric cancer patients who are malnourished prior to treatment faced worse treatment outcomes compared to those who maintained proper nutrition, according to... Read More
Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer
Chemotherapy after surgery for gastric cancer was superior to chemoradiation in a recent trial.
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
The PD-L1 inhibitor Bavencio, when given as maintenance therapy to gastric cancer patients in a trial, was not superior to chemotherapy, but... Read More
Blood test picks out cancers likely to benefit from targeted drugs
British researchers discovered that a blood test could identify gastric cancer patients who might benefit from EGFR-inhibiting drugs.